MALVERN, Pa.–(BUSINESS WIRE)–NexEos Bio Vision Health (“NexEos”), a clinical-stage biopharmaceutical company developing novel therapies and diagnostics targetingMALVERN, Pa.–(BUSINESS WIRE)–NexEos Bio Vision Health (“NexEos”), a clinical-stage biopharmaceutical company developing novel therapies and diagnostics targeting

NexEos Bio Announces FDA Clearance of IND Application to Proceed to Phase II/III Trial of NTX-1024 in Vernal Keratoconjunctivitis

2026/02/20 00:01
3 min di lettura
Per feedback o dubbi su questo contenuto, contattateci all'indirizzo [email protected].

MALVERN, Pa.–(BUSINESS WIRE)–NexEos Bio Vision Health (“NexEos”), a clinical-stage biopharmaceutical company developing novel therapies and diagnostics targeting eosinophil-mediated diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared NexEos’s Investigational New Drug (IND) Application to proceed to a Phase II/III clinical trial of NTX-1024 for the treatment of patients with the rare disease, vernal keratoconjunctivitis (VKC). The planned Phase II/III trial is a single, randomized, double-masked, vehicle-controlled trial to evaluate the safety and efficacy of NTX-1024 ophthalmic solution in patients with VKC.

This is on the heels of the positive results reported from an open-label, investigator-initiated study evaluating the efficacy, safety, and tolerability of NTX-1024 eye drops in adults with VKC. The study was conducted in Mexico and enrolled 15 patients with mild to moderate VKC who received NTX-1024 four times daily over a four-week period. Treatment led to significant improvement in patient-reported symptoms such as itching and quality of life, along with reductions in clinical signs of inflammation, including hyperemia and corneal fluorescein staining. NTX-1024 was also found to be safe and well-tolerated.

This marks the first clinical study to evaluate NTX-1024 in VKC, a rare and severe eosinophil-driven ocular condition that can lead to irreversible ocular damage, including vision loss, if left untreated. These results reinforce the therapeutic potential of NTX-1024 in VKC and have prompted NexEos to pursue further clinical development.

In addition, on January 16, 2026, the FDA granted Orphan Drug Designation to NTX-1024 for VKC.

“Clearance of our IND application, which included data from our open-label investigator-initiated study in Mexico, is an important and meaningful step for the program,” said Steve Tullman, CEO and Chairman of NexEos. “We are excited to advance clinical development of NTX-1024, which would be the first, ophthalmic therapeutic to neutralizes eosinophil cationic protein to reduce inflammation in rare forms of Allergic Conjunctivitis – Vernal Keratoconjunctivitis (VKC) and Atopic Keratoconjunctivitis (AKC). We are on track to initiate our Phase II/III clinical trial by the second half of this year, taking us closer to our objective of delivering a best-in-class therapeutic option to patients with VKC.”

About Vernal Keratoconjunctivitis (VKC)

VKC is a rare, chronic, and vision-threatening ocular inflammatory disease that is predominantly eosinophil-mediated. Activated eosinophils release toxic granule proteins, including eosinophil major basic protein-1 (eMBP1), resulting in damage to the ocular surface (Sacchetti, et al. 2021). VKC primarily affects children although approximately 10% of cases persist into adulthood (Di Zazzo A 2024). Uncontrolled VKC can result in severe ocular damage and permanent vision loss (Vichyanond, et al. 2014).

About NTX-1024 (gleceparin sodium)

NTX-1024 is a novel, topical ophthalmic solution targeting eosinophil cationic protein mediated inflammation in rare forms of allergic conjunctivitis, including VKC and AKC. NTX-1024 has completed proof of concept in VKC, received ODD approval, and now has FDA clearance of its IND application to advance to a Phase II/III clinical trial in VKC. NTX-1024 is the first therapeutic successfully targeting neutralization of eosinophil cationic proteins. Finally, NTX-1024 has the potential to be the first drug to be disease-modifying and steroid-sparing in VKC and AKC.

About NexEos Bio

NexEos Bio (www.nexeosbio.com) is a privately held medical diagnostics and therapeutics company based in Malvern, Pennsylvania, dedicated to improving the detection, diagnosis, treatment and life-long management of patients living with chronic, eosinophil-related inflammatory diseases. Through the licensing, development and commercialization of novel technologies, NexEos Bio is bringing new tools and therapies to market that address the unmet needs of patients suffering from eosinophil-related diseases.

Contacts

For more Information, please send inquiries to: [email protected]

Opportunità di mercato
Logo NuNet
Valore NuNet (NTX)
$0.0056
$0.0056$0.0056
-0.35%
USD
Grafico dei prezzi in tempo reale di NuNet (NTX)
Disclaimer: gli articoli ripubblicati su questo sito provengono da piattaforme pubbliche e sono forniti esclusivamente a scopo informativo. Non riflettono necessariamente le opinioni di MEXC. Tutti i diritti rimangono agli autori originali. Se ritieni che un contenuto violi i diritti di terze parti, contatta [email protected] per la rimozione. MEXC non fornisce alcuna garanzia in merito all'accuratezza, completezza o tempestività del contenuto e non è responsabile per eventuali azioni intraprese sulla base delle informazioni fornite. Il contenuto non costituisce consulenza finanziaria, legale o professionale di altro tipo, né deve essere considerato una raccomandazione o un'approvazione da parte di MEXC.

Potrebbe anche piacerti

Let insiders trade – Blockworks

Let insiders trade – Blockworks

The post Let insiders trade – Blockworks appeared on BitcoinEthereumNews.com. This is a segment from The Breakdown newsletter. To read more editions, subscribe ​​“The most valuable commodity I know of is information.” — Gordon Gekko, Wall Street Ten months ago, FBI agents raided Shayne Coplan’s Manhattan apartment, ostensibly in search of evidence that the prediction market he founded, Polymarket, had illegally allowed US residents to place bets on the US election. Two weeks ago, the CFTC gave Polymarket the green light to allow those very same US residents to place bets on whatever they like. This is quite the turn of events — and it’s not just about elections or politics. With its US government seal of approval in hand, Polymarket is reportedly raising capital at a valuation of $9 billion — a reflection of the growing belief that prediction markets will be used for much more than betting on elections once every four years. Instead, proponents say prediction markets can provide a real service to the world by providing it with better information about nearly everything. I think they might, too — but only if insiders are free to participate. Yesterday, for example, Polymarket announced new betting markets on company earnings reports, with a promise that it would improve the information that investors have to work with.  Instead of waiting three months to find out how a company is faring, investors could simply watch the odds on Polymarket.  If the probability of an earnings beat is rising, for example, investors would know at a glance that things are going well. But that will only happen if enough of the people betting actually know how things are going. Relying on the wisdom of crowds to magically discern how a business is doing won’t add much incremental knowledge to the world; everyone’s guesses are unlikely to average out to the truth. If…
Condividi
BitcoinEthereumNews2025/09/18 05:16
Tether CEO Delivers Rare Bitcoin Price Comment

Tether CEO Delivers Rare Bitcoin Price Comment

Bitcoin price receives rare acknowledgement from Tether CEO Ardoino
Condividi
Coinstats2025/09/17 23:39
Cloud mining is gaining popularity around the world. LgMining’s efficient cloud mining platform helps you easily deploy digital assets and lead a new wave of crypto wealth.

Cloud mining is gaining popularity around the world. LgMining’s efficient cloud mining platform helps you easily deploy digital assets and lead a new wave of crypto wealth.

The post Cloud mining is gaining popularity around the world. LgMining’s efficient cloud mining platform helps you easily deploy digital assets and lead a new wave of crypto wealth. appeared on BitcoinEthereumNews.com. SPONSORED POST* As the cryptocurrency market continues its recovery, Ethereum has once again become the center of attention for investors. Recently, the well-known crypto mining platform LgMining predicted that Ethereum may surpass its previous all-time high and surge past $5,000. In light of this rare market opportunity, choosing a high-efficiency, secure, and low-cost mining platform has become the top priority for many investors. With its cutting-edge hardware, intelligent technology, and low-cost renewable energy advantages, LgMining Cloud Mining is rapidly emerging as a leader in the cloud mining industry. Ethereum: The Driving Force of the Crypto Market Ethereum is not only the second-largest cryptocurrency by market capitalization but also the backbone of the blockchain smart contract ecosystem. From DeFi (Decentralized Finance) to NFTs (Non-Fungible Tokens) and the broader Web3.0 infrastructure, most innovations are built on Ethereum. This widespread utility gives Ethereum tremendous growth potential. With the upcoming scalability upgrades, the Ethereum network is expected to offer improved performance and transaction speed—likely triggering a fresh wave of market enthusiasm. According to the LgMining research team, Ethereum’s share among institutional and retail investors continues to grow. Combined with shifting monetary policies and global economic uncertainties, Ethereum is expected to break past its previous high of over $4,000 and aim for $5,000 or more in the coming months. LgMining Cloud Mining: Unlocking a Low-Barrier Path to Wealth Traditional crypto mining often requires expensive mining rigs, stable electricity, and complex maintenance—making it inaccessible for the average person. LgMining Cloud Mining breaks down these barriers, allowing anyone to easily participate in mining Ethereum and Bitcoin without owning hardware. LgMining builds its robust and efficient mining infrastructure around three core advantages: 1. High-End Equipment LgMining uses top-tier mining hardware with exceptional computing power and reliability. The platform’s ASIC and GPU miners are carefully selected and tested to…
Condividi
BitcoinEthereumNews2025/09/18 03:04